Regions
MAIN/REGIONS
regions/
Regions
  1. Americas
  2. Asia & Oceania
  3. Europe
  4. Middle East & Africa
  1. Who We Help
  2. Insights
  3. Events
  4. Contact Us
MAIN/search
MAIN/Who We Help
Who We Help/
WHO WE HELP
  • Pharmaceutical Manufacturers
  • Emerging Biopharma
  • MedTech
  • Financial Institutions
  • Government and Public Health
  • Health Plans
  • Hospital and Health Systems
  • Insurers and Risk
  • Medical Specialty and Patient Advocacy
Pharmaceutical Manufacturers

Harness unparalleled healthcare data, advanced analytics, and cutting-edge technologies with our expertise to accelerate the development and commercialization of innovative medicines, enhancing patient lives.

Harness Data
Pharmaceutical Manufacturers
Emerging Biopharma (Global page)

Boost your innovation with IQVIA's expert team. Our comprehensive solutions integrate top-tier insights, technology, and expertise to maximize your asset's success in a competitive landscape.

Discover Innovations
MedTech

Navigating MedTech's unique landscape: U.S. decision-making now rests with GPOs, IDNs, and payers, who demand solid value proof through rigorous outcomes analyses and pricing scrutiny.

Explore MedTech
MedTech
Financial Institutions

Invest in healthcare with confidence. Stay ahead of pharma and medical device trends using real-time, high-quality data. Access market insights, historical sales, prescription trends, and emerging product information for informed, risk-reduced decisions.

Access Insights
Government and Public Health

Unlock deeper health insights with unmatched data and innovative technology to enhance decision-making for your essential government programs.

Unlock Innovations
Government and Public Health
Health Plans

Accelerate digital innovation with our data-driven expertise in data science and healthcare, optimizing business processes for smarter decisions.

Navigate Health Plans
Hospital and Health Systems

Leverage digital innovation to cut costs, boost efficiency, and elevate patient engagement, all while enhancing quality and health outcomes.

Streamline Decisions
Hospital and Health Systems
Insurers and Risk

Enhance your ability to evaluate and forecast population risk swiftly and accurately by integrating unmatched data, expertise, and technology.

Evaluate Risk
Medical Specialty and Patient Advocacy

Transform into a data-driven organization that enhances your specialty and showcases value to your members through digital transformation.

Enhance Your Specialty
MAIN/Insights
Insights/
U.S. PROGRESS POINT

A curation of IQVIA's best thinking on topics and trends driving change, disruption, and progress in the United States healthcare market.

LEARN MORE
BLOGS, WHITE PAPERS & CASE STUDIES

Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.

DISCOVER INSIGHTS

PODCASTS

"Discover the future through our enlightening podcasts available in the United States.

EXPLORE PODCASTS

FACT SHEET

"IQVIA AI Medical Record Review

LEARN MORE

BLOG

"Decoding DSCSA: Ensuring Compliance in the Pharmaceutical Supply Chain

READ MORE
MAIN/Events
Events/
ON-DEMAND WEBINARS

Visit our library of on-demand webinars.

WATCH ON-DEMAND WEBINARS
UPCOMING EVENTS & WEBINARS

View our upcoming events and webinars.

DISCOVER EVENTS & WEBINARS

EVENT

"26th Controlled Substances and State Regulatory Conference

REGISTER NOW
MAIN/Contact Us
Contact Us/
MARKET ACCESS

Understanding the 340B Drug Discount Program

The 340B Drug Discount Program is a federal program in which manufacturers provide Medicaid-like discounts on covered outpatient drugs to qualifying hospitals and clinics. The program is highly complex and non-transparent, and IQVIA can help you understand how it's evolving.
Contact us
Locations United States Our U.S. Solutions Life Sciences Commercial Solutions Market Access Solutions Contract and Revenue Management Gross-to-Net 340B Drug Discount Program

EVOLUTION OF THE 340B PROGRAM

How 340B Works

Fact Sheet
Unintended Consequences: How the Affordable Care Act Helped Grow the 340B Program
White Paper
Unintended Consequences: How the Affordable Care Act Helped Grow the 340B Program
White Paper
The 340B Drug Discount Program Grew to $124B in 2023
Fact Sheet
Research Summary: The Cost of the 340B Program Part 2: 340B Revenue Sharing
Fact Sheet
Research Summary: The Cost of the 340B Program Part 1: Self-Insured Employers
White Paper
The Cost of the 340B Program Part 2: 340B Revenue Sharing
White Paper
The Cost of the 340B Program Part 1: Self-Insured Employers
Fact Sheet
Are 340B Discounts Directly Subsidizing Insured Patients or their Plans?
White Paper
Are 340B Discounts Directly Subsidizing Insured Patients or their Plans?
White Paper
Are Discounts in the 340B Drug Discount Program Being Shared with Patients at Contract Pharmacies?
White Paper
Can 340B Modifiers Avoid Duplicate Discounts in the IRA?
White Paper
The 340B Drug Discount Program: Complexity, Challenges, and Change
Prev
Next

EVOLUTION OF THE 340B PROGRAM

340B Size and Growth

Fact Sheet
Double Trouble: How Expanding Eligibility Could Double the Size of the 340B Program
White Paper
Double Trouble: How Expanding Eligibility Could Double the Size of the 340B Program
White Paper
The 340B Drug Discount Program Exceeds $100B in 2022
Blog
340B Program Continues to Grow While Contract Pharmacy Restrictions Take Effect
By: Rory Martin
Blog
Growth of the 340B Program Accelerates in 2020
By: Rory Martin, Shiraz Hasan
Blog
340B Drug Discount Program Growth Drivers
By: Shiraz Hasan, Sofi Peterson
Prev
Next

340B patient discount sharing

One of the defining features of the 340B program is there's no requirement for 340B discounts to directly benefit patients: 340B revenue is given to 340B hospitals and clinics which may use it to support activities such as uncompensated care programs. IQVIA is conducting a series of studies of how much 340B revenue is being shared directly with patients, and which kinds of patients are benefiting.
REVIEW THE INSIGHTS

Impact of The Inflation Reduction Act on 340B

The Inflation Reduction Act (IRA) of 2022 introduced provisions requiring the identification and removal of 340B transactions from Medicare to avoid duplicate discounts. CMS has proposed the use of 340B modifiers—flags on claims indicating the use of 340B product—to achieve this. IQVIA has explored the usage of 340B modifiers and how they will impact the industry going forward.
EXPLORE THE IMPACT
Rory Martin

PhD, Senior Principal, Market Access Center of Excellence

Contact Us